相关实验视频
Updated: Jul 28, 2025
07:38
Strategies for Assessing Autistic-Like Behaviors in Mice
Published on: September 20, 2024
1.1K
对于自闭症谱系障碍的乙胆酶抑制剂
Alexandra Ure1,2,3, Georgina R Cox1,4, Richard Haslam5,6
1Department of Paediatrics, Monash University, Melbourne, Australia.
The Cochrane database of systematic reviews
|June 2, 2023
概括
对自闭症中乙胆酶抑制剂的证据非常不确定. 这些药物对自闭症核心特征几乎没有影响,可能会增加不良事件,需要进一步研究.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 发育儿科 发育儿科
背景情况:
- 自闭症谱系障碍 (ASD) 是一种影响社会沟通和行为的神经发育状况.
- 乙胆是一种神经递质,因其在注意力和记忆中的作用而与ASD有关.
- 乙胆酶抑制剂 (AChEI) 正在研究ASD的潜在治疗效果.
研究的目的:
- 评估ACHEI对自闭症核心和非核心特征的疗效和安全性.
- 评估AChEI对ASD个体的社交互动,沟通和重复行为的影响.
主要方法:
- 随机对照试验 (RCT) 的系统综述,比较AChEIs (加兰他胺,多尼佩西尔,里瓦斯蒂格明) 与安慰剂.
- 纳入标准:具有临床自闭症诊断的个人,任何年龄.
- 主要结局:核心自闭症特征和不良影响;次要结局:语言,易怒,多动,一般健康.
主要成果:
- 包括两个RCT (74名参与者). 对加兰他胺的证据显示,在社交沟通或重复行为方面几乎没有差异,潜在的不良事件可能更高.
- 对多尼佩西尔的证据显示,在核心自闭症特征上没有差异,对次要结果和潜在的不良事件的影响非常不确定.
- 由于存在偏见和不准确性高风险,总体证据质量非常低.
结论:
- 目前关于AChEI对自闭症核心特征的有效性的证据在成年人中缺乏,在儿童中非常不确定.
- 需要更多的研究来确定ACHEI在改善自闭症患者的治疗结果方面的临床实用性.
- 目前正在进行的研究可能会进一步了解ACHEI在自闭症治疗中的作用.
相关概念视频
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
721
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
721
01:22Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226
01:19Autism Spectrum Disorder
167
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
167
01:26Anticholinesterase Agents: Poisoning and Treatment
928
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
928
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
610
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
610